Onkológia 1/2010
A new trend in targeted (biologic) therapy of non-small cell lung cancer in the 2009 – maintenance therapy
Targeted therapy of non-small cell lung cancer is at present time standard type of care. In the first line bevacizumab with standard chemotherapy regimens is widely used. In second and higher lines is commonly used erlotinib. Maintenance therapy with bevacizumab and erlotinib after initial standard chemotherapy improved therapeutical outcomes in group patients with poor prognosis.
Keywords: non-small cell lung cancer, bevacizumab, erlotinib, ATLAS & SATURN clinical study
